Direct-acting antiviral therapy reduces variceal rebleeding and improves liver function in hepatitis C virus-related cirrhosis: A multicenter retrospective cohort study

Table 8 Competing risk analysis for liver-related vs non-liver-related mortality

Variable	Subdistribution HR (95%CI)	P value
Liver-related mortality
DAA treatment	0.35 (0.20-0.61)	< 0.001
MELD score > 10	1.89 (1.23-2.91)	0.004
Child-Pugh Class B	1.56 (1.02-2.38)	0.039
Non-liver-related mortality
DAA treatment	1.10 (0.80-1.50)	0.560
Age > 50 years	1.45 (1.02-2.06)	0.038
Hypertension	1.20 (0.90-1.60)	0.210

A competing risk analysis was performed using the Fine and Gray subdistribution hazard model. Liver-related mortality included deaths due to hepatic failure, variceal bleeding, and other liver-related complications. Non-liver-related mortality included deaths due to cardiovascular events, infections, and other non-liver causes. MELD: Model for end-stage liver disease; DAA: Direct-acting antiviral.